Evoke Wealth’s LENZ Therapeutics LENZ Stock Holding History

Evoke Wealth’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,276	Closed	-$292K	–	739
2025 Q3	$292K	Buy	+6,276	New	+$231K	0.01%	504

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Evoke Wealth's LENZ Position: Q4 2025 in Review

Evoke Wealth sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 6,276 shares — an estimated $292K sold.

Evoke Wealth first reported a position in LENZ in Q3 2025 and held it in 1 quarter. The position peaked at $292K in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

Evoke Wealth reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
Evoke Wealth sold 6,276 LENZ Therapeutics shares in Q4 2025, an estimated $292K.
Evoke Wealth first reported a position in LENZ Therapeutics in Q3 2025 and held it in 1 quarter.
Evoke Wealth's LENZ Therapeutics position peaked at $292K in Q3 2025.
160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Evoke Wealth's 13F filing for Q4 2025, filed 6 Feb 2026.